301 related articles for article (PubMed ID: 21701499)
1. Accelerating access to treatments for rare diseases.
Dunoyer M
Nat Rev Drug Discov; 2011 Jun; 10(7):475-6. PubMed ID: 21701499
[TBL] [Abstract][Full Text] [Related]
2. Rare diseases, orphan drugs and their regulation: questions and misconceptions.
Tambuyzer E
Nat Rev Drug Discov; 2010 Dec; 9(12):921-9. PubMed ID: 21060315
[TBL] [Abstract][Full Text] [Related]
3. Incentives for orphan drug research and development in the United States.
Seoane-Vazquez E; Rodriguez-Monguio R; Szeinbach SL; Visaria J
Orphanet J Rare Dis; 2008 Dec; 3():33. PubMed ID: 19087348
[TBL] [Abstract][Full Text] [Related]
4. Ethical imperatives of timely access to orphan drugs: is possible to reconcile economic incentives and patients' health needs?
Rodriguez-Monguio R; Spargo T; Seoane-Vazquez E
Orphanet J Rare Dis; 2017 Jan; 12(1):1. PubMed ID: 28057032
[TBL] [Abstract][Full Text] [Related]
5. Incentivizing Orphan Product Development: United States Food and Drug Administration Orphan Incentive Programs.
Le TT
Adv Exp Med Biol; 2017; 1031():183-196. PubMed ID: 29214572
[TBL] [Abstract][Full Text] [Related]
6. The US Orphan Drug Act: rare disease research stimulator or commercial opportunity?
Wellman-Labadie O; Zhou Y
Health Policy; 2010 May; 95(2-3):216-28. PubMed ID: 20036435
[TBL] [Abstract][Full Text] [Related]
7. R&D and market size: Who benefits from orphan drug legislation?
Gamba S; Magazzini L; Pertile P
J Health Econ; 2021 Dec; 80():102522. PubMed ID: 34530381
[TBL] [Abstract][Full Text] [Related]
8. The impact of the Orphan Drug Act on Food and Drug Administration-approved therapies for rare skin diseases and skin-related cancers.
Karas L; Lu CY; Agrawal PB; Asgari MM
J Am Acad Dermatol; 2019 Sep; 81(3):867-877. PubMed ID: 31103566
[TBL] [Abstract][Full Text] [Related]
9. Adopting orphan drugs--two dozen years of treating rare diseases.
Haffner ME
N Engl J Med; 2006 Feb; 354(5):445-7. PubMed ID: 16452556
[No Abstract] [Full Text] [Related]
10. The impact of the Orphan Drug Act on the development and advancement of neurological products for rare diseases: a descriptive review.
Burke KA; Freeman SN; Imoisili MA; Coté TR
Clin Pharmacol Ther; 2010 Oct; 88(4):449-53. PubMed ID: 20856241
[TBL] [Abstract][Full Text] [Related]
11. Rare-disease drugs to receive consideration on par with serious-disease drugs.
Thompson CA
Am J Health Syst Pharm; 2012 Nov; 69(22):1936-7. PubMed ID: 23135552
[No Abstract] [Full Text] [Related]
12. Modifying the Criteria for Granting Orphan Drug Market Exclusivity.
Socal MP; Parasrampuria S; Anderson GF
Value Health; 2020 Nov; 23(11):1470-1476. PubMed ID: 33127018
[TBL] [Abstract][Full Text] [Related]
13. Novel Treatments for Rare Cancers: The U.S. Orphan Drug Act Is Delivering-A Cross-Sectional Analysis.
Stockklausner C; Lampert A; Hoffmann GF; Ries M
Oncologist; 2016 Apr; 21(4):487-93. PubMed ID: 27022038
[TBL] [Abstract][Full Text] [Related]
14. Effective Market Exclusivity of New Molecular Entities for Rare and Non-rare Diseases.
Kerr KW; Glos LJ
Pharmaceut Med; 2020 Feb; 34(1):19-29. PubMed ID: 32048213
[TBL] [Abstract][Full Text] [Related]
15. Rare Diseases: Addressing the Challenges in Diagnosis, Drug Approval, and Patient Access.
Copley-Merriman K
Value Health; 2018 May; 21(5):491-492. PubMed ID: 29753343
[No Abstract] [Full Text] [Related]
16. A clinical pharmacology-regulatory perspective on the approval of drugs for rare diseases.
Bashaw ED
Clin Pharmacol Ther; 2016 Oct; 100(4):327-9. PubMed ID: 27417549
[TBL] [Abstract][Full Text] [Related]
17. Rare diseases, orphan drugs, and orphaned patients.
Scheindlin S
Mol Interv; 2006 Aug; 6(4):186-91. PubMed ID: 16960139
[No Abstract] [Full Text] [Related]
18. The Orphan Drug Act Revisited.
Thomas S; Caplan A
JAMA; 2019 Mar; 321(9):833-834. PubMed ID: 30768155
[No Abstract] [Full Text] [Related]
19. Regulators adopt more orphan drugs.
Reardon S
Nature; 2014 Apr; 508(7494):16-7. PubMed ID: 24695293
[No Abstract] [Full Text] [Related]
20. What the Orphan Drug Act has done lately for children with rare diseases: a 10-year analysis.
Thorat C; Xu K; Freeman SN; Bonnel RA; Joseph F; Phillips MI; Imoisili MA
Pediatrics; 2012 Mar; 129(3):516-21. PubMed ID: 22371464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]